198 related articles for article (PubMed ID: 19383607)
1. The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells.
D'mello V; Singh S; Wu Y; Birge RB
J Biol Chem; 2009 Jun; 284(25):17030-17038. PubMed ID: 19383607
[TBL] [Abstract][Full Text] [Related]
2. High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.
Yang A; Dai J; Xie Z; Colman RW; Wu Q; Birge RB; Wu Y
J Immunol; 2014 May; 192(9):4398-408. PubMed ID: 24688027
[TBL] [Abstract][Full Text] [Related]
3. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
4. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
[TBL] [Abstract][Full Text] [Related]
5. Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1).
Bass R; Ellis V
Thromb Haemost; 2009 May; 101(5):954-62. PubMed ID: 19404550
[TBL] [Abstract][Full Text] [Related]
6. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
[TBL] [Abstract][Full Text] [Related]
7. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration.
Yebra M; Parry GC; Strömblad S; Mackman N; Rosenberg S; Mueller BM; Cheresh DA
J Biol Chem; 1996 Nov; 271(46):29393-9. PubMed ID: 8910604
[TBL] [Abstract][Full Text] [Related]
8. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
9. Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.
Briassouli P; Komissarova EV; Clancy RM; Buyon JP
Circ Res; 2010 Aug; 107(3):374-87. PubMed ID: 20558828
[TBL] [Abstract][Full Text] [Related]
10. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
11. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
[TBL] [Abstract][Full Text] [Related]
12. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
Annis MG; Ouellet V; Rennhack JP; L'Esperance S; Rancourt C; Mes-Masson AM; Andrechek ER; Siegel PM
Breast Cancer Res; 2018 Jan; 20(1):9. PubMed ID: 29382358
[TBL] [Abstract][Full Text] [Related]
13. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
14. Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.
Bifulco K; Longanesi-Cattani I; Franco P; Pavone V; Mugione P; Di Carluccio G; Masucci MT; Arra C; Pirozzi G; Stoppelli MP; Carriero MV
PLoS One; 2012; 7(9):e44806. PubMed ID: 23049759
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
16. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells.
Simon DI; Rao NK; Xu H; Wei Y; Majdic O; Ronne E; Kobzik L; Chapman HA
Blood; 1996 Oct; 88(8):3185-94. PubMed ID: 8874219
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator receptor is required for impairing toll-like receptor 7 signaling on macrophage efferocytosis in lupus.
Li J; Pan Y; Li D; Xia X; Jiang Q; Dou H; Hou Y
Mol Immunol; 2020 Nov; 127():38-45. PubMed ID: 32911323
[TBL] [Abstract][Full Text] [Related]
18. Participation of the urokinase receptor in neutrophil efferocytosis.
Park YJ; Liu G; Tsuruta Y; Lorne E; Abraham E
Blood; 2009 Jul; 114(4):860-70. PubMed ID: 19398720
[TBL] [Abstract][Full Text] [Related]
19. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
20. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
